


PHARMACEUTICAL 2020

RVL Pharmaceuticals plc Rank 217 of 362







PHARMACEUTICAL 2020

RVL Pharmaceuticals plc Rank 217 of 362



The relative strengths and weaknesses of RVL Pharmaceuticals plc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of RVL Pharmaceuticals plc compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 203% points. The greatest weakness of RVL Pharmaceuticals plc is the variable Other Expenses, reducing the Economic Capital Ratio by 197% points.

The company's Economic Capital Ratio, given in the ranking table, is -240%, being 63% points above the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	172,630
Cost of Goods Sold	111,630
Intangible Assets	254,841
Liabilities, Current	75,937
Liabilities, Non-Current	272,486
Other Assets	5,546
Other Compr. Net Income	-383
Other Expenses	256,626
Other Liabilities	124
Other Net Income	-17,327
Property and Equipment	30,238
Research and Development	32,319
Revenues	240,031
Selling, General and Administrative Expense	93,030

Output Variable	Value in 1000 USD
Assets	463,255
Liabilities	348,547
Expenses	493,605
Stockholders Equity	114,708
Net Income	-270,901
Comprehensive Net Income	-271,092
Economic Capital Ratio	-240%